Prognostic Value of miR-1826 in Prostate Cancer and Its Regulatory Effect on Tumor Progression

References

• Peng P, Chen T, Wang Q, et al. Decreased miR-218-5p levels as a serum biomarker in bone metastasis of prostate cancer. Oncol Res Treat. 2019;42(4):165–185. doi:10.1159/000495473
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang Q, Guo B, et al. miR-1231 is downregulated in prostate cancer with prognostic and functional implications. Oncol Res Treat. 2020;43(3):78–86. doi:10.1159/000504606
   PubMed Web of Science ®Google Scholar
• Hirata H, Hinoda Y, Ueno K, et al. MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer. Carcinogenesis. 2012;33(1):41–48. doi:10.1093/carcin/bgr239
   PubMed Web of Science ®Google Scholar
• Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079–1092. doi:10.1016/j.eururo.2012.02.054
   PubMed Web of Science ®Google Scholar
• Peng P, Gong YM, Bao PP, et al. [Estimates and prediction of prostate cancer incidence, mortality and prevalence in China, 2008]. Zhonghua Liu Xing Bing Xue Za Zhi. 2012;33:1056–1059. [ Chinese]
   PubMedGoogle Scholar
• Cai J, Yang F, Zhan H, et al. RNA m(6)A methyltransferase METTL3 promotes the growth of prostate cancer by regulating hedgehog pathway. Onco Targets Ther. 2019;12:9143–9152. doi:10.2147/OTT.S226796
   PubMed Web of Science ®Google Scholar
• Yu H, Pan J, Guo Z, et al. CART cell therapy for prostate cancer: status and promise. Onco Targets Ther. 2019;12:391–395. doi:10.2147/OTT.S185556
   PubMed Web of Science ®Google Scholar
• Xu B, Lu X, Zhao Y, et al. MicroRNA-135a induces prostate cancer cell apoptosis via inhibition of STAT6. Oncol Lett. 2019;17:1889–1895. doi:10.3892/ol.2018.9791
   PubMed Web of Science ®Google Scholar
• Gao G, Xiu D, Yang B, et al. miR-129-5p inhibits prostate cancer proliferation via targeting ETV1. Onco Targets Ther. 2019;12:3531–3544. doi:10.2147/OTT.S183435
   PubMedGoogle Scholar
• Zhang H, Lian Z, Sun G, et al. Loss of miR-516a-3p mediates upregulation of ABCC5 in prostate cancer and drives its progression. Onco Targets Ther. 2018;11:3853–3867. doi:10.2147/OTT.S167463
   PubMed Web of Science ®Google Scholar
• Petrovic N, Davidovic R, Bajic V, et al. MicroRNA in breast cancer: the association with BRCA1/2. Cancer Biomark. 2017;19(2):119–128. doi:10.3233/CBM-160319
   PubMed Web of Science ®Google Scholar
• Zhang LY, Chen Y, Jia J, et al. MiR-27a promotes EMT in ovarian cancer through active Wnt/ signalling by targeting FOXO1. Cancer Biomark. 2019;24(1):31–42. doi:10.3233/CBM-181229
   PubMed Web of Science ®Google Scholar
• Zheng C, Guo K, Chen B, et al. miR-214-5p inhibits human prostate cancer proliferation and migration through regulating CRMP5. Cancer Biomark. 2019;26(2):193–202. doi:10.3233/CBM-190128
   PubMed Web of Science ®Google Scholar
• Antognelli C, Cecchetti R, Riuzzi F, et al. Glyoxalase 1 sustains the metastatic phenotype of prostate cancer cells via EMT control. J Cell Mol Med. 2018;22(5):2865–2883. doi:10.1111/jcmm.13581
   PubMed Web of Science ®Google Scholar
• Mohammadi Torbati P, Asadi F, Fard-Esfahani P. Circulating miR-20a and miR-26a as biomarkers in prostate cancer. Asian Pac J Cancer Prev. 2019;20(5):1453–1456. doi:10.31557/APJCP.2019.20.5.1453
   PubMedGoogle Scholar
• Bi CW, Zhang GY, Bai Y, et al. Increased expression of miR-153 predicts poor prognosis for patients with prostate cancer. Medicine. 2019;98(36):e16705. doi:10.1097/MD.0000000000016705
   PubMed Web of Science ®Google Scholar
• Chen L, Hu W, Li G, et al. Inhibition of miR-9-5p suppresses prostate cancer progress by targeting StarD13. Cell Mol Biol Lett. 2019;24(1):20. doi:10.1186/s11658-019-0145-1
   PubMed Web of Science ®Google Scholar
• Haj-Ahmad TA, Abdalla MA, Haj-Ahmad Y. Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. J Cancer. 2014;5(3):182–191. doi:10.7150/jca.6799
   PubMed Web of Science ®Google Scholar
• Li M, Pan M, You C, et al. The therapeutic potential of miR-7 in cancers. Mini Rev Med Chem. 2019;19(20):1707–1716. doi:10.2174/1389557519666190904141922
   PubMed Web of Science ®Google Scholar
• Iacona JR, Lutz CS. miR-146a-5p: expression, regulation, and functions in cancer. Wiley Interdiscip Rev RNA. 2019;10:e1533. doi:10.1002/wrna.1533
   PubMed Web of Science ®Google Scholar
• Zhang L, Liao Y, Tang L. MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. J Exp Clin Cancer Res. 2019;38(1):53. doi:10.1186/s13046-019-1059-5
   PubMed Web of Science ®Google Scholar
• Wang Z, Sha HH, Li HJ. Functions and mechanisms of miR-186 in human cancer. Biomed Pharmacother. 2019;119:109428. doi:10.1016/j.biopha.2019.109428
   PubMed Web of Science ®Google Scholar
• Iqbal MA, Arora S, Prakasam G, et al. MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance. Mol Aspects Med. 2019;70:3–20. doi:10.1016/j.mam.2018.07.003
   PubMed Web of Science ®Google Scholar
• Adhami M, Haghdoost AA, Sadeghi B, et al. Candidate miRNAs in human breast cancer biomarkers: a systematic review. Breast Cancer. 2018;25(2):198–205. doi:10.1007/s12282-017-0814-8
   PubMed Web of Science ®Google Scholar
• Aghdam AM, Amiri A, Salarinia R, et al. MicroRNAs as diagnostic, prognostic, and therapeutic biomarkers in prostate cancer. Crit Rev Eukaryot Gene Expr. 2019;29(2):127–139. doi:10.1615/CritRevEukaryotGeneExpr.2019025273
   PubMed Web of Science ®Google Scholar
• Ray J, Hoey C, Huang X, et al. MicroRNA‑198 suppresses prostate tumorigenesis by targeting MIB1. Oncol Rep. 2019;42:1047–1056. doi:10.3892/or.2019.7234 
   PubMed Web of Science ®Google Scholar
• Zhang X, Jin K, Luo JD, et al. MicroRNA-107 inhibits proliferation of prostate cancer cells by targeting cyclin E1. Neoplasma. 2019;66(05):704–716. doi:10.4149/neo_2018_181105N825
   PubMedGoogle Scholar
• Hirata H, Hinoda Y, Ueno K, et al. MicroRNA-1826 directly targets beta-catenin (CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer. Carcinogenesis. 2012;33(3):501–508. doi:10.1093/carcin/bgr302
   PubMed Web of Science ®Google Scholar
• Hu Y, Yi B, He S, et al. Clinical significance of miR-1826 as a novel prognostic biomarker in colorectal cancer. Anticancer Agents Med Chem. 2016;16(9):1109–1116. doi:10.2174/1871520615666150507122434
   PubMed Web of Science ®Google Scholar
• Kiss O, Tőkés AM, Spisák S, et al. Breast- and salivary gland-derived adenoid cystic carcinomas: potential post-transcriptional divergencies. A pilot study based on miRNA expression profiling of four cases and review of the potential relevance of the findings. Pathol Oncol Res. 2015;21(1):29–44. doi:10.1007/s12253-014-9770-1
   PubMed Web of Science ®Google Scholar
• Chen S, Lao J, Geng Q, et al. A 3-microRNA signature identified from serum predicts clinical outcome of the locally advanced gastric cancer. Front Oncol. 2020;10:565. doi:10.3389/fonc.2020.00565
   PubMed Web of Science ®Google Scholar
• Meng L, Li Z, Chen Y, et al. LINC00689 promotes prostate cancer progression via regulating miR-496/CTNNB1 to activate Wnt pathway. Cancer Cell Int. 2020;20:215. doi:10.1186/s12935-020-01280-1
   PubMed Web of Science ®Google Scholar
• Parashar D, Geethadevi A. Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L/CRR9-mediated chemotherapeutic drug resistance. NPJ Precis Oncol. 2021;5:16. doi:10.1038/s41698-021-00152-9
   PubMed Web of Science ®Google Scholar
• Parashar D, Geethadevi A, Aure MR, et al. miRNA551b-3p activates an oncostatin signaling module for the progression of triple-negative breast cancer. Cell Rep. 2019;29(13):4389–4406.e4310. doi:10.1016/j.celrep.2019.11.085
   PubMed Web of Science ®Google Scholar